Iovance Biotherapeutics Up 16% After Insiders Buy Shares
marketwatch.com
news
2022-06-03 18:05:00

By Josh Beckerman Iovance Biotherapeutics Inc. shares were up 16% to $7.64 after five Form 4 filings late Thursday detailed stock purchases by company insiders, including board member Wayne Rothbaum, who bought 1 million shares. Shares fell sharply a week ago after the company provided an update on a study of its lead product candidate lifileucel in advanced melanoma. Write to Josh Beckerman at josh.beckerman@wsj.com
